Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

CAP TODAY

New guidance on lung cancer testing

April 2013—It was a monumental task: create a molecular testing guideline for lung cancer. Among other tasks, those involved (representing the CAP, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology) reviewed 1,533 abstracts and read, in detail, 521 full-text articles. There was extensive evidence grading; naturally, new literature was published in the interim, which required even more reviews. The payoff was the first international, evidence-based, multidisciplinary guideline for this part of lung cancer care. It contains 37 items addressing 14 subjects, including 15 recommendations (evidence grade A/B).

From the President’s Desk: At CAP ’13, countless ways to connect

April 2013—Our 11th CAP annual meeting will open Oct. 13 in Orlando with a scientific plenary tied to this year’s “dig deeper” track (13 courses) in endocrine pathology. Three renowned experts will present “Metabolic Syndrome: Can the Controversy Become Pathology’s Opportunity?” and launch four days of outstanding education and networking.

New attention on POC device disease transmission

April 2013—When 19th-century Hungarian obstetrician Ignaz Semmelweis found that doctors could dramatically decrease puerperal infections by washing their hands with a chlorinated lime solution before delivering babies, his colleagues thought he was nuts. Why, everyone knew that infections were caused by noxious air!

Order more tests? With diabetes, answer may be ‘yes’

March 2013—In patients with diabetes mellitus, hemoglobin A1c testing frequency is largely in line with recommended guidelines. In those same patients, LDL testing is not performed frequently enough, and urine protein testing frequency falls far short of recommendations.

Policing blood use pays off for Allina Laboratories

March 2013—A January study of almost 1,000 patients with acute gastrointestinal bleeding has found that restrictive blood transfusion strategies produce better patient outcomes. The study, “Transfusion strategies for acute upper gastrointestinal bleeding,” discovered that patients with severe acute upper GI bleeding who received blood transfusions when their hemoglobin levels fell below 7 g/dL, rather than 9 g/dL, had higher probabilities of survival at six weeks, as well as reduced rates of further bleeding and fewer adverse events (Villanueva C, et al. N Engl J Med. 2013;368:11–21).

Molecular walk-through for CRC testing

March 2013—For pathologists and clinicians alike, molecular testing can carry shades of a Pinter play: a seemingly straightforward situation with a whiff of discomfort, if not outright menace, and bedeviled by shifting characters and layers of meaning that defy snap interpretations.

TB or not TB? Newer assays settle in

March 2013—Though tuberculosis is primarily diagnosed and treated in the public health system, there’s a need for greater knowledge about TB in the private sector, says Sundari Mase, MD, MPH, of the CDC’s Field Services and Evaluation Branch, Division of Tuberculosis Elimination. Among private physicians, she says, “there is little institutional knowledge about TB.” When Dr. Mase sees patients, often she’ll note diagnostic delays in recognizing TB, “delays that occur because physicians aren’t thinking about TB.”

Houston study augurs possible shift in hrHPV genotypes

March 2013—First identified in an HIV patient in 1998, HPV 90 is a genotype of the human papillomavirus that, until now, has received little attention. It is not counted as one of the few well-defined high-risk genotypes, like HPV 16 and HPV 18, that are known to cause the majority of cervical cancer cases.

Steep climb to suitable reference standards

February 2013—It’s a long way from ancient Greek philosophers to modern-day clinical laboratory directors. Yet both types of scholars have one thing in common: the pursuit of truth. Socrates and his disciples thought of truth as correspondence to an objective universal ideal in the mind. Today’s clinical laboratory scientists need a more concrete standard against which to measure their results, leading to the continuing search for suitable reference materials to be used in method development, test validation, internal QC, assay calibration, and proficiency testing.